Partruvix (pamiparib) / BeOne Medicines - LARVOL DELTA

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=404 | Active, not recruiting | Sponsor: BeOne Medicines | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=430 | Enrolling by invitation | Sponsor: BeOne Medicines | Trial completion date: Dec 2026 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Neoadjuvant Pamiparib in Newly Diagnosed Advanced Ovarian Cancer: A Single-Arm, Prospective Phase II Trial (SGO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Ovarian Cancer • Solid Tumor

Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report. (PubMed, Cancer Rep (Hoboken)) - "This case suggests that the combination of denosumab with PARP inhibitors and chemoradiotherapy may provide a potential therapeutic strategy for TNBC patients with bone metastasis. Further studies are warranted to validate the efficacy and safety of this combined treatment approach."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HRD

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=29 | Completed | Sponsor: Sun Yat-sen University | Recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Jan 2026

Platinum resistant • Trial completion • Trial completion date • Carcinosarcoma • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Sarcoma • Solid Tumor

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: University of Chicago | Trial completion date: Jan 2026 ➔ Jan 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2028

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-1 • PD-L1

A Phase II Single-Arm, Open-Label Trial of Pamiparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with Deleterious Germline or Somatic BRCA1/2 Alterations or Homologous Recombination Deficiency (HRD) (EAU 2026) - No abstract available

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study. (PubMed, Ther Adv Med Oncol) - "In total, 62 MBC patients treated with olaparib (N = 55), talazoparib (N = 4), pamiparib (N = 2), and fluzoparib (N = 1) were enrolled. Hematologic toxicity was the most common grade ⩾3 AEs. PARPis showed promising PFS and tolerable toxicity in the real-world treatment of Chinese MBC patients with HRR-related gene mutations."

Journal • Real-world evidence • Retrospective data • Breast Cancer • Hematological Disorders • Leukopenia • Oncology • Solid Tumor • BRCA1 • BRCA2 • HRD

BGB-290-302: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - P3 | N=224 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Jun 2027 ➔ Jan 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2025

Platinum sensitive • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor

Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study. (PubMed, Prostate Cancer Prostatic Dis) - "Neoadjuvant pamiparib plus abiraterone and ADT demonstrated efficacy, safety, and potential QoL benefits in HRPCa/VHRPCa."

Journal • P2 data • Dyslipidemia • Genito-urinary Cancer • Hematological Disorders • Hypertriglyceridemia • Oncology • Prostate Cancer • Solid Tumor • Urinary Incontinence • Urology • HRD

PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov) - P1 | N=78 | Active, not recruiting | Sponsor: University of California, San Francisco | Recruiting ➔ Active, not recruiting

Enrollment closed • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • IDH1 • IDH2

Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment. (PubMed, Front Pharmacol) - "In vivo, significant downregulation of p-PI3K, p-Akt, Bcl-2, and HIF1-α, and upregulation of BAX protein expression confirmed that the mechanism of action of combination therapy is related to PI3K/Akt pathway. The combination of PAM and ANL was more effective than monotherapy for treating ovarian cancer and holds potential to become a new therapeutic approach for ovarian cancer."

IO biomarker • Journal • Oncology • Ovarian Cancer • Solid Tumor • ANXA5 • BAX • BCL2 • HIF1A

Broad-spectrum anti-influenza activity of the NMPA-approved drug Pamiparib is uncovered by virtual docking to the evolutionarily conserved domain of IAV-M2 protein. (PubMed, Bioorg Med Chem) - "In addition, pamiparib suppresses effectively viral infection in vivo. Ultimately, this study verifies that antiviral drugs designed to target the evolutionarily conserved regions of the influenza virus M2 protein indeed possess broad-spectrum antiviral activity across different strains."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. (PubMed, Pharmacol Res) - "The FDA has approved four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) for the treatment of ovarian, breast, prostate, and pancreatic cancer...The Chinese NMPA has approved three PARP antagonists (fuzuloparib, pamiparib, senaparib) for the treatment of ovarian cancer. All seven of these drugs are orally bioavailable and fall within the criteria of Lipinski's rule of five. Drug resistance develops in most PARP-inhibitor-treated cancer patients within one or two years."

Journal • Review • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

A prospective, randomized, open-label, controlled clinical study comparing ivosimod combined with chemotherapy versus pamiparib combined with chemotherapy as neoadjuvant therapy for NSCLC (ChiCTR) - P2 | N=168 | Recruiting | Sponsor: Peking University People's Hospital; Peking University People's Hospital

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma. (PubMed, Curr Oncol) - P1/2 | "Treatment-emergent cytopenia was manageable and reversible with dose reductions/interruptions. Combination regimens demonstrated antitumor activity."

Journal • P1/2 data • Brain Cancer • Glioblastoma • Hematological Disorders • Oncology • Solid Tumor • MGMT

Quality of Life Analysis in Patients with High-Risk Localized Prostate Cancer Receiving Neoadjuvant Pamiparib plus Abiraterone and ADT: A Prospective Study [WITHDRAWN] (ESMO 2025) - No abstract available

Clinical • HEOR • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy and safety profiles of PARP inhibitors in Chinese patients with metastatic breast cancer: A multi-center real-world study (ESMO 2025) - "Results 62 MBC patients treated with olaparib (n = 55), talazoparib (n = 4), pamiparib (n = 2) and fluzoparib (n = 1) were analyzed. Conclusions PARPis showed promising PFS and tolerable toxicity in the real-word treatment of Chinese patients with metastatic breast cancer. Legal entity responsible for the study The authors."

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • CDK12 • CHEK1 • HER-2 • HRD • PALB2 • RAD51C

Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas. (PubMed, Neuro Oncol) - "Pamiparib appeared to achieve sufficient pharmacologically active concentrations in both enhancing and non-enhancing tumors. While some patients achieved prolonged progression-free survival, combination with temozolomide did not produce a meaningful ORR in IDHmt recurrent gliomas. Cumulative hematologic toxicity was substantial and impacted long-term tolerability."

Journal • P1/2 data • Brain Cancer • Glioma • Hematological Disorders • Neutropenia • Oncology • Solid Tumor

Molecular and morphological features of blood vessels in tumour margin regions of glioblastoma are distinct from tumour core and normal brain, and drug delivery is reduced (EANO 2025) - "Material and Longitudinal measurement (11 samples, 8 hours) of free extracellular levels of PARP inhibitors pamiparib (high brain penetrance) and olaparib (low penetrance) was performed by microdialysis in tumour core, margin and contralateral brain in GBM xenografted CD1 nude mice. Dynamic microdialysis studies show that the PARP inhibitor olaparib penetrates tumour margin regions at lower concentrations than core. Towards understanding this effect, multiplex IHC has revealed two types of vessels in margin regions: almost 50% resembled normal brain vessels but with altered levels of claudin-5, while the others shared morphological properties with a subpopulation of tumour core vessels."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD31 • CLDN5 • PDGFRB • PECAM1

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma (Multidisciplinary Digital Publishing Institute) - "Disease control and objective response rates were 67.9% and 11.3%, respectively, for treatment-naïve patients in the dose-escalation and -expansion studies, and 40.9% and 13.6%, respectively, for recurrent/refractory patients. Median overall survival for treatment-naïve MGMT unmethylated patients was 12.8 months and 7.3 months for recurrent/refractory MGMT methylated and unmethylated patients."

P1/2 data • Glioblastoma

A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments. (PubMed, Front Oncol) - "After initial surgery and adjuvant imatinib, the tumor recurred. Through comprehensive analysis of gene mutation profiles (KIT and HRR gene mutations, including BRCA2), a combination therapy of fluzoparib, pamiparib, and ripretinib was administered, stabilizing the patient's condition with significant efficacy. This case highlights the importance of genetic testing and personalized targeted treatment strategies for gastrointestinal stromal tumor (GIST) patients."

Journal • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • BRCA2 • HRD • KIT

A novel 18F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1 (SNMMI 2025) - "Blocking studies with AZD9574, Olaparib, Rucaparib, Veliparib, and Pamiparib significantly reduced intracellular radiotracer uptake, while no significant reduction was observed with UPF-1035, a PARP2-specific inhibitor (Fig. The radiotracer 18F-AZD9574 was synthesized following a previously established protocol (Fig. 1A). Western blot analysis confirmed substantial PARP1 expression in the U87-MG (glioblastoma), 22Rv1 (prostate), PSN-1 (pancreatic), MDA-MB-436 (breast), and MDA-MB-231 (breast) cancer cell lines (Fig."

Brain Cancer • Breast Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor • PARP1 • PARP2

Imaging Parthanatos in Animal Models of Parkinson’s disease (SNMMI 2025) - "In vitro PARP1 immunostaining and autoradiography (AR) using the PARP radioligand [18F]BGB290 were used to compare with the PET imaging results... Immunostaining revealed elevated PARP1 expression in the striatum of the PFF-injected mice (Figure 1A). The PET imaging showed higher SUV at the ipsilateral (Ipsi) striatum of the PFF-injected mice compared to the contralateral striatum, while the hippocampus showed no significant changes between the two groups, consistent with the spreading pattern of α-syn in this animal model. Increased DVRs were observed in striatum-Ipsi (42%, p < 0.05) and the whole brain (20%, p < 0.05)."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology